Earnings season is upon us, so we decided to ask our top health care contributors to identify the stock they're watching to surprise on earnings. Here are the companies they singled out.
Cubist is set to report second-quarter earnings on July 22 after the bell. The Street is expecting earnings per share of $0.02 on $299.6 million in revenue for the quarter. Consensus has nonetheless fallen dramatically over the course of the quarter for two reasons.
Firstly, Cubist is gearing up to launch Sivextro, indicated for acute bacterial skin and skin structure infections, thus increasing operational costs. More importantly, the Street lost faith in Cubicin's growth story after the drug posted weak sales numbers in the first-quarter of 2014.
And that's where I think the Street will get caught flat-footed this quarter. Cubist's management decided to maintain its full year guidance of $1.19 to $1.275 billion following its first-quarter hiccup, whereas many analysts lowered their projections to around a billion.
What's important to understand is that Cubicin's growth is supposed to be uneven due to seasonality in the marketplace. Put simply, I think revenues will come in closer to $310 million for the second quarter based on a seasonal upswing in Cubicin sales.
Although just 26 states (plus DC) are embracing Medicaid expansion, the Centers for Medicare and Medicaid report that six million people have signed up for Medicaid coverage following the ACA's launch last fall. That brought total Medicaid enrollment to 65 million people at the end of April, up 10% from last October.
Surging enrollment is good news for insurers administering state programs, but it's particularly good news for specialty insurers like Molina given that the vast majority of Molina's revenue is tied to Medicaid. Molina's sales jumped 21% in the first quarter thanks in part to 47,000 new Medicaid members in California.
A big backlog of Medicaid applicants in California (several hundred thousand applications still need to be processed as of last week) continues to provide a tailwind, but Michigan should help Molina's quarter too. Molina served 218,000 Medicaid members in Michigan exiting Q1, but that number should jump given that Michigan reported signing up 323,000 new Medicaid members over the past 14 weeks.
First quarter sales were nearly $2.3 billion, and prescription data for the hepatitis C drug suggests that sales should be higher in the second quarter since prescriptions continued to climb until the beginning of May before flattening out. It's hard to know exactly how much higher because discounts aren't known and prescription data isn't 100% accurate, but a $3-billion quarter isn't out of the question according to ISI analyst Mark Schoenebaum.
The surprise could come in what Gilead says about the potential for sales in the current quarter. With an all-oral combination of Sovaldi and Gilead's ledipasvir potentially being approved in October, doctors may warehouse patients, waiting for the easier-to-take cocktail.
While warehousing would delay payment, it would ultimately be good news for Gilead because many of the patients are currently being treated with a combination of Sovaldi and Johnson & Johnson's Olysio. If patients delay treatment, Gilead can capture the full sales value for those patients, assuming Sovaldi-ledipasvir costs more than Sovaldi alone.
Leaked: A huge market-shocking opportunity
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.
The Motley Fool recommends Cubist Pharmaceuticals, Gilead Sciences, and Johnson & Johnson. The Motley Fool owns shares of Cubist Pharmaceuticals, Gilead Sciences, and Johnson & Johnson. Todd Campbell owns shares of Gilead and Molina. George Budwell owns shares of Gilead. Brian Orelli has no positions in any stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.